Advertisement
Canada markets close in 4 hours 38 minutes

  • S&P/TSX

    21,608.51
    -131.69 (-0.61%)
     

  • S&P 500

    5,051.62
    -10.20 (-0.20%)
     

  • DOW

    37,795.27
    +60.16 (+0.16%)
     

  • CAD/USD

    0.7233
    -0.0020 (-0.28%)
     

  • CRUDE OIL

    85.58
    +0.17 (+0.20%)
     

  • Bitcoin CAD

    86,139.04
    -3,279.06 (-3.67%)
     

  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     

  • GOLD FUTURES

    2,404.70
    +21.70 (+0.91%)
     

  • RUSSELL 2000

    1,961.17
    -14.54 (-0.74%)
     

  • 10-Yr Bond

    4.6470
    +0.0190 (+0.41%)
     

  • NASDAQ

    15,870.58
    -14.44 (-0.09%)
     

  • VOLATILITY

    18.80
    -0.43 (-2.24%)
     

  • FTSE

    7,817.89
    -147.64 (-1.85%)
     

  • NIKKEI 225

    38,471.20
    -761.60 (-1.94%)
     

  • CAD/EUR

    0.6803
    -0.0021 (-0.31%)
     
MARKETS LIVE BLOG:

STOCKS TRADE MIXED AS COMPANY EARNINGS ROLL IN

Shares of Live Nation, parent company of Ticketmaster, fall on antitrust probe report

Cara Therapeutics to Host Capital Markets Day on Thursday, February 16, 2023

Cara Therapeutics, Inc.
·2 min read
Cara Therapeutics, Inc.
Cara Therapeutics, Inc.

STAMFORD, Conn., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the Company will host an in-person and virtual Capital Markets Day in New York City on Thursday, February 16, 2023, from 10:00 a.m. to 1:00 p.m. EST.

The event will highlight the launch of KORSUVA® (difelikefalin) injection and feature presentations during which healthcare providers will discuss the unmet medical need in pruritus associated with non-dialysis dependent chronic kidney disease, atopic dermatitis and notalgia paresthetica. The Company’s registrational Phase 2/3 program of oral difelikefalin in notalgia paresthetica patients with moderate-to-severe pruritus will also be discussed.

Presenters will include:

ADVERTISEMENT

  • Christopher Posner, President and Chief Executive Officer, Cara Therapeutics

  • Joana Goncalves, M.D., Chief Medical Officer, Cara Therapeutics

  • Eric Vandal, Senior Vice President, Commercial, Cara Therapeutics

  • Joel Topf, M.D., FACP, Assistant Clinical Professor of Medicine at Oakland University William Beaumont School of Medicine, and Medical Director of St. Clair Nephrology Research

  • Jennifer Scherer, M.D., Assistant Professor of Palliative Care and Nephrology at the NYU Grossman School of Medicine, and Director of the Kidney CARES Program at NYU Langone Health

  • Raj Chovatiya, M.D., Ph.D., Assistant Professor of Dermatology at the Northwestern University Feinberg School of Medicine, and Director of the Center for Eczema and Itch at Northwestern University

  • Shawn Kwatra, M.D., FAAD, Assistant Professor of Dermatology at the Johns Hopkins University School of Medicine, and Director of the Johns Hopkins Itch Center

To register for the event, please click here.

A live webcast of the event will be accessible under “Events & Presentations” in the News & Investors section of the Company’s website at www.CaraTherapeutics.com. A replay of the webcast will be archived on the Company’s website following the event.

About Cara Therapeutics

Cara Therapeutics is a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus. The Company’s novel KORSUVA® (difelikefalin) injection is the first and only FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. The Company is developing an oral formulation of difelikefalin and has initiated Phase 3 programs for the treatment of pruritus in patients with non-dialysis dependent advanced chronic kidney disease and atopic dermatitis. The Company has completed a Phase 2 proof-of-concept trial of oral difelikefalin for the treatment of moderate-to-severe pruritus in patients with notalgia paresthetica and plans to initiate a Phase 2/3 clinical trial program in the first quarter of 2023. For more information, visit www.CaraTherapeutics.com and follow the company on Twitter, LinkedIn and Instagram.

MEDIA CONTACT:
Annie Spinetta
6 Degrees
973-768-2170
aspinetta@6degreespr.com

INVESTOR CONTACT:
Iris Francesconi, Ph.D.
Cara Therapeutics
203-406-3700
investor@caratherapeutics.com